Bifogade filer
Kurs & Likviditet
Kalender
Tid* | ||
2025-05-20 | 09:00 | Kvartalsrapport 2025-Q1 |
2025-05-20 | - | Årsstämma |
2025-02-25 | 08:00 | Bokslutskommuniké 2024 |
2024-11-19 | 09:00 | Kvartalsrapport 2024-Q3 |
2024-08-27 | - | Kvartalsrapport 2024-Q2 |
2024-05-22 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
2024-05-21 | - | Årsstämma |
2024-05-21 | - | Kvartalsrapport 2024-Q1 |
2024-02-20 | - | Extra Bolagsstämma 2024 |
2024-02-20 | - | Bokslutskommuniké 2023 |
2023-11-10 | - | Kvartalsrapport 2023-Q3 |
2023-08-22 | - | Kvartalsrapport 2023-Q2 |
2023-05-24 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
2023-05-23 | - | Årsstämma |
2023-05-23 | - | Kvartalsrapport 2023-Q1 |
2023-02-15 | - | Bokslutskommuniké 2022 |
2022-11-16 | - | Kvartalsrapport 2022-Q3 |
2022-08-23 | - | Kvartalsrapport 2022-Q2 |
2022-05-11 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
2022-05-10 | - | Kvartalsrapport 2022-Q1 |
2022-05-10 | - | Årsstämma |
2022-03-29 | - | Extra Bolagsstämma 2022 |
2022-02-22 | - | Bokslutskommuniké 2021 |
2021-11-11 | - | Kvartalsrapport 2021-Q3 |
2021-07-13 | - | Kvartalsrapport 2021-Q2 |
2021-05-20 | - | Split SYNT 1:10 |
2021-05-12 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
2021-05-11 | - | Årsstämma |
2021-05-11 | - | Kvartalsrapport 2021-Q1 |
2021-02-18 | - | Bokslutskommuniké 2020 |
2020-11-12 | - | Kvartalsrapport 2020-Q3 |
2020-10-02 | - | X-dag ordinarie utdelning SYNT 1.50 SEK |
2020-07-14 | - | Kvartalsrapport 2020-Q2 |
2020-05-05 | - | Årsstämma |
2020-05-05 | - | Kvartalsrapport 2020-Q1 |
2020-02-27 | - | Bokslutskommuniké 2019 |
2019-11-12 | - | Kvartalsrapport 2019-Q3 |
2019-07-14 | - | Kvartalsrapport 2019-Q2 |
2019-04-30 | - | X-dag ordinarie utdelning SYNT 1.50 SEK |
2019-04-29 | - | Kvartalsrapport 2019-Q1 |
2019-04-29 | - | Årsstämma |
2019-02-27 | - | Bokslutskommuniké 2018 |
2018-11-16 | - | Kvartalsrapport 2018-Q3 |
2018-08-22 | - | Kvartalsrapport 2018-Q2 |
2018-04-26 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
2018-04-25 | - | Kvartalsrapport 2018-Q1 |
2018-04-25 | - | Årsstämma |
2018-02-21 | - | Bokslutskommuniké 2017 |
2017-11-10 | - | Kvartalsrapport 2017-Q3 |
2017-08-24 | - | Kvartalsrapport 2017-Q2 |
2017-04-26 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
2017-04-25 | - | Årsstämma |
2017-04-25 | - | Kvartalsrapport 2017-Q1 |
2017-02-15 | - | Bokslutskommuniké 2016 |
2016-10-28 | - | Kvartalsrapport 2016-Q3 |
2016-08-26 | - | Kvartalsrapport 2016-Q2 |
2016-04-27 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
2016-04-26 | - | Årsstämma |
2016-04-26 | - | Kvartalsrapport 2016-Q1 |
2016-02-26 | - | Bokslutskommuniké 2015 |
2015-10-30 | - | Kvartalsrapport 2015-Q3 |
2015-08-28 | - | Kvartalsrapport 2015-Q2 |
2015-04-13 | - | Årsstämma |
2015-04-13 | - | Kvartalsrapport 2015-Q1 |
2015-02-17 | - | X-dag ordinarie utdelning SYNT 0.00 SEK |
2015-02-13 | - | Bokslutskommuniké 2014 |
2014-11-28 | - | Kvartalsrapport 2014-Q3 |
2014-09-26 | - | Extra Bolagsstämma 2014 |
2014-08-29 | - | Kvartalsrapport 2014-Q2 |
Beskrivning
Land | Sverige |
---|---|
Lista | Spotlight |
Sektor | Hälsovård |
Industri | Medicinteknik |
SyntheticMR announced today that their next-generation imaging solution with isotropic resolution, SyMRI 3D, is FDA-pending for clinical use in the United States.
[image]
"We are thrilled to receive 510(k) pending status for SyMRI 3D," says Ulrik Harrysson, CEO at SyntheticMR AB. "SyMRI 3D represents a pivotal leap forward in medical imaging, offering new possibilities for diagnosis and treatment."
SyMRI 3D is poised to revolutionize the field of medical imaging by introducing a myriad of innovative applications within SyMRI's post-processing solution. SyMRI 3D enables precise volumetric estimations of brain regions, a technique commonly referred to as parcellation, which empowers clinicians to gain deeper insights into brain structure and function.
Furthermore, the exceptional resolution provided by SyMRI 3D facilitates comprehensive lesion analysis, ensuring a more accurate and in-depth assessment of medical conditions.
"This advanced SyMRI sequence introduces 3D resolution to quantitative values and tissue segmentations, ensuring the same level of precision in quantification as achieved with SyMRI's 2D imaging," says Kyle Frye, CCO & President of SyntheticMR Inc. "Receiving 510(k) clearance for SyMRI 3D will allow us to enable physicians to make better, more informed decisions using quantitative imaging."
For additional information, please contact Ulrik Harrysson, CEO, SyntheticMR AB, +46 70 529 29 87 ulrik.harrysson@syntheticmr.com or KyleFrye, President SyntheticMR Inc. at +1 (859) 512-9496 or kyle.frye@syntheticmr.com.